3 research outputs found
Conversión de prueba cutánea de derivado proteico purificado durante el tratamiento con anti-TNF-α
Introducción: los anti-TNF-α se asocian con mayor riesgo de desarrollar tuberculosis (TB). La prueba del derivado proteico purificado (purified protein derivative, PPD) se emplea para diagnosticar infección de tuberculosis latente (ITL). Se recomienda el cribado para TB previo al inicio de terapia anti-TNF-α y el seguimiento para evaluar la posible conversión de la PPD durante el tratamiento. El tratamiento de la ITL puede reducir el riesgo de desarrollar enfermedad activa en un 90%.
Objetivos: actualmente los resultados de conversión de la PPD y su interpretación durante el tratamiento anti-TNF-α son variables, por tal motivo nos propusimos conocer la frecuencia de conversión de la PPD en este grupo de pacientes de nuestro medio
A multicenter prospective study of 515 febrile neutropenia episodes in Argentina during a 5-year period
For better management of patients with febrile neutropenia, our study investigated the epidemiologic, microbiologic, and clinical characteristics of adult inpatients with febrile neutropenia and their mortality-associated factors. To this end, we carried out a prospective, observational, multicenter study in 28 Argentinian hospitals between 2007 and 2012. We included 515 episodes of febrile neutropenia from 346 patients, median age 49 years. Neutropenia followed chemotherapy in 77% of cases, half of the cases due to hematological malignancies. Most episodes were classified as high-risk according to MASCC criteria, and 53.6% of patients were already hospitalized at the onset of febrile neutropenia. Bloodstream infections were detected in 14% episodes; whereas an infectious source of fever was identified in 80% of cases. Mortality rate achieved to 14.95%. The binary regression analysis showed that persistence of fever at day 7, or neutropenia at day 14, dehydration and tachycardia at the onset of febrile neutropenia as well as prior infections were significantly associated with mortality. In addition to expanding our current knowledge on the features of adult patients with febrile neutropenia, present findings provide useful information for better management of them in Argentina, given the appropriate representativeness of centers participating in the study.Fil: Parodi, Roberto Leandro. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Rosario; ArgentinaFil: Lagrutta, Mariana. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Rosario; ArgentinaFil: Tortolo, Mauro. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Rosario; ArgentinaFil: Navall, EstefanÃa. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Rosario; ArgentinaFil: RodrÃguez, MarÃa S. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Rosario; ArgentinaFil: Sasia, Gervasio F. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Rosario; ArgentinaFil: de Candia, Lucas F. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Rosario; ArgentinaFil: Gruvman, Matias A. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Rosario; ArgentinaFil: Bottasso, Oscar. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Rosario; ArgentinaFil: Greca, Alcides Alejandro. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Rosario; Argentin
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
BACKGROUND:
Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.
METHODS:
ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy.
RESULTS:
Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events.
CONCLUSION:
ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk